The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.

Dickon HayneKatherine OngNicole SwarbrickSteve P McCombieAndrew MoeCynthia HawksPravin ViswambaramCiara ConduitElizabeth LiowLisa SpaldingJayne LimThomas FergusonKatie MeehanIan D DavisAndrew D Redfern

Published in: BJU international (2024)

Sub-urothelial injection of durvalumab is feasible and safe without immune-related AEs and shows local immunological effects.

Keyphrases

phase iii
study protocol
high grade
phase ii
clinical trial
endothelial cells
urinary tract
ultrasound guided
randomized controlled trial
pluripotent stem cells